Zhigan Jiang

This inventor holds 23 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 11 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Medshine Discovery Inc., Shandong Danhong Pharmaceutical Co., Ltd., Guangdong Raynovent Biotech Co., Ltd.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhigan Jiang. Retrieved from https://idiyas.com/inventor/zhigan-jiang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 6)

% Patents Active = 95.7

CIPO Patents = 5 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 26)

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

6 out of 72

Medshine Discovery Inc.

patents

5 out of 10

Shandong Danhong Pharmaceutical Co., Ltd.

patents

2 out of 13

Guangdong Raynovent Biotech Co., Ltd.

patents

4. 2 out of 2

Heilongjiang Zhenbaodao Pharmaceutical Co, Ltd

patents

5. 2 out of 15

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

patents

6. 1 out of 2

Cisen Pharmaceutical Co., Ltd

patents

7. 1 out of 7

Cisen Pharmaceutical Co., Ltd.

patents

8. 1 out of 1

Conjustar (Zhuhai) Biologics Co., Ltd.

patent

9. 1 out of 7

Fujian Akeylink Biotechnology Co., Ltd.

patents

10. 1 out of 1

Fujian Akeylink Biotechnology Co., Ltd.

patent

11. 1 out of 3

Fujian Cosunter Pharmaceutical Co., Ltd.

patents

12. 1 out of 3

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory

patents

13. 1 out of 4

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.

Phaeno Therapeutics Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

CRAC Inhibitors

Antiviral Agents

PPAR Agonists

Thiazole Derivatives

Tri-cycle Compounds

Aminopyridine Compounds

Imidazole Derivatives

Quinolone Derivatives

Crystal Forms

KHK Inhibitory Compounds

Modified Andrographolide

Tricyclic Polypeptides

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758548 - Piperazine derivatives and application thereof (2026-10-13),

2. 12583846 - 2H-benzopyran derivatives as CRAC inhibitors (2026-03-24),

3. 12569500 - Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV (2026-03-10),

4. 12539335 - TRICYCLIC POLYPEPTIDE CONJUGATED DRUG AND USE THEREOF (2026-02-03),

5. 12534477 - Compound having KHK inhibitory effect (2026-01-27),

6. 12492169 - Aminopyridine compound and application thereof (2025-12-09),

7. 11964969 - Crystal forms of thiazole compound and application thereof (2024-04-23),

8. 11952388 - Crystal form of tri-cycle compound and application thereof (2024-04-09),

9. 11680070 - Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof (2023-06-20),

10. 11673899 - Crystal form of thieno[2,3-c]pyridazine-4(1H)-one compound, preparation method therefor and use thereof (2023-06-13),

11. 11578081 - Crystal form as inhibitor of ACC1 and ACC2, and preparation method therefor and use thereof (2023-02-14),

12. 11396493 - Amorphous pyrrolidine derivative as PPAR agonist and preparation method thereof (2022-07-26),

13. 11299482 - Salt and crystal form of modified andrographolide compound and preparation method thereof (2022-04-12),

14. 11053260 - Tri-cycle compound and applications thereof (2021-07-06),

15. 10858322 - Process for preparing 1-isobutyryl-1'-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo[D]imidazol-2-yl)methyl)spiro[azetidine-3,3′-indolin]-2′-one (2020-12-08),

Title: Unveiling the Innovations of Inventor Zhigan Jiang from Shanghai

Introduction:

Zhigan Jiang, a prolific inventor hailing from the bustling city of Shanghai, CN, has made significant contributions to the field of pharmaceuticals with a remarkable total of 17 patents to his name. His groundbreaking inventions have revolutionized the treatment of various diseases, particularly those associated with the herpes simplex virus and HBV-related conditions.

Latest Patents:

1. Crystal forms of thiazole compound and application thereof: Jiang's latest patent unveils crystal form A of a compound represented by formula (I), a compound represented by formula (II), and crystal form B, showcasing their potential application in developing drugs for diseases linked to the herpes simplex virus.

2. Crystal form of tri-cycle compound and application thereof: Another innovative patent by Jiang features crystal forms A and B of a compound described by formula (I), illustrating their utilization in creating medications for HBV-related illnesses.

Career Highlights:

Throughout his career, Jiang has honed his expertise in the pharmaceutical sector through pivotal roles at renowned companies such as Medshine Discovery Inc. and Shandong Danhong Pharmaceutical Co., Ltd. His innovative spirit and dedication to advancing healthcare have led to the successful development and patenting of numerous novel technologies.

Collaborations:

Jiang's impactful work would not have been possible without the collaboration of esteemed colleagues like Haiying He and Shuhui Chen. Together, they have synergized their talents to drive forward cutting-edge research initiatives and bring revolutionary inventions to fruition.

Conclusion:

Inventor Zhigan Jiang stands as a beacon of innovation in the realm of pharmaceuticals, with his trailblazing patents paving the way for novel treatment approaches in combating various diseases. His collaborations and career milestones underscore his unwavering commitment to advancing healthcare through inventive solutions, making him a true visionary in the field.

Profile summary based on public USPTO records.